$ 1280.00
axolGEM iPSC-Derived Neural Stem Cells LRRK2 G2019S HOM (1.5 million cells) and Neural Plating-XF Medium (30 mL)
Payment Options
We accept Visa and MasterCard in our online store.
Worldwide Shipping
We can get your purchases to you wherever you are.
Customer Care
As an Axol customer you have access to our support team and product specialists.
Description
Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation. Click on the product images to see the data and further details.
Click here to see more data on Axol Neural Stem Cells
The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).
Product Specification
| Starting material | Dermal fibroblast |
| Donor gender | Female |
| Donor age at sampling | 64 yrs |
| Karyotype | Normal |
| Reprogramming method | Episomal vector |
| Induction method | Monolayer & chemically defined medium |
| Genetic modification | Homozygous for the LRRK2 G2019S mutation (GGC>AGC) |
| Genetic modification | Contains a puromycin resistance cassette (intronic) |
| Size | ≥1.5 million cells |
| Kit components | 1 vial of axolGEM Neural Stem Cells (≥1.5 million cells) and 1 bottle of Plating-XF Medium (30 mL) |
| Growth properties | Adherent |
| Shipping conditions | Dry ice |
| Storage conditions | Liquid nitrogen |
Technical Resources
References
- Read nowThaler A, Ash E, Gan-Or Z et al. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. Journal of Neural Transmission (2009)
- Read nowWest AB, Moore DJ, Biskup S et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA (2005)
- Read nowDi Fonzo A, Tassorelli C, De Mari M et al: Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet (2006)
